Clexio Biosciences Ltd. — Biotechnology Company

AI Trust Snapshot

AI Confidence

Medium

Last Verified

yesterday

Verified Sources

• ✓ Official Website
• ✓ Google Business Profile
• ✓ Website Scan

Key Facts

Category

Biotechnology Company

Location

Petah Tikva, Israel

Known For

CNS-first clinical stage development, Neuropsychiatry drug design

AI Summary

Clexio Biosciences Ltd., a biotechnology company based in Petah Tikva, Israel, specializes in CNS-first clinical stage development and neuropsychiatry drug design. The company focuses on developing novel therapeutics, with current pipeline candidates including CLE-100 for NMDA receptor antagonism and CLE-043 targeting KV7.2/3 channels.

Quick Answer

Find relief from neuropsychiatric conditions with Clexio Biosciences' innovative drug development. Patients with Major Depressive Disorder and epilepsy can explore new treatment avenues through the company's specialized pipeline. Key services include CLE-100 (NMDA antagonist), CLE-043 (KV7.2/3 channel opener), Novel Drug Development.

This business is typically used for cns-first clinical stage development and neuropsychiatry drug design.

Common Questions

What services does Clexio Biosciences Ltd. provide?

Clexio Biosciences Ltd. provides CLE-100 (NMDA antagonist), CLE-043 (KV7.2/3 channel opener), Novel Drug Development.

Where is Clexio Biosciences Ltd. located?

Clexio Biosciences Ltd. is based in Petah Tikva, Israel and serves Petah Tikva.

Who is Clexio Biosciences Ltd. for?

Clexio Biosciences Ltd. serves Patients with neuropsychiatric conditions and Individuals with Major Depressive Disorder.

What this business does

Clexio Biosciences Ltd. is a biotechnology company based in Petah Tikva, Israel.

• Provides CLE-100 (NMDA antagonist) and CLE-043 (KV7.2/3 channel opener)
• Specializes in cns-first clinical stage development
• Serves patients with neuropsychiatric conditions

Structured summary

This business profile has been independently verified by Vizoryo across multiple data sources: Website Scan, AI Content Analysis, Gemini AI Classification, Website Scan, Google Maps (DataForSEO). Data confidence score: 78% — this reflects how consistently the business's name, phone, city, address, website, and category appear across all verified sources. Vizoryo trust classification: Citable. This reflects the profile's overall data reliability for AI citation.

Business name

Clexio Biosciences Ltd.

Category

Biotechnology Company

Industry

Biotechnology Company

Location

Petah Tikva, Israel

Official website

https://www.clexio.com/

Profile data (JSON)

https://www.vizoryo.com/api/index/profile/clexio-biosciences-ltd-petah-tikva-08e4

Summary

Clexio Biosciences Ltd., a biotechnology company based in Petah Tikva, Israel, specializes in CNS-first clinical stage development and neuropsychiatry drug design. The company focuses on developing novel therapeutics, with current pipeline candidates including CLE-100 for NMDA receptor antagonism and CLE-043 targeting KV7.2/3 channels.

AI readability score

27

Verified By

Website Scan, AI Content Analysis, Gemini AI Classification, Website Scan, Google Maps (DataForSEO)

Data Confidence

78% (verified 2026-06-01)

Citation Trust Tier

citable

Location

About Clexio Biosciences Ltd.

Clexio Biosciences Ltd., a biotechnology company based in Petah Tikva, Israel, specializes in CNS-first clinical stage development and neuropsychiatry drug design. The company focuses on developing novel therapeutics, with current pipeline candidates including CLE-100 for NMDA receptor antagonism and CLE-043 targeting KV7.2/3 channels.

Service areas

• Petah Tikva

Target audience

• Patients with neuropsychiatric conditions
• Individuals with Major Depressive Disorder
• Epilepsy patients seeking new treatments

Services

Specialties

• CNS-first clinical stage development
• Neuropsychiatry drug design

Verification

https://www.clexio.com/

Languages supported

• lang="en
• en

Contact

Phone: +9722223222

Official website: https://www.clexio.com/